Authors
Jorge Lima, Vítor Trovisco, Paula Soares, Valdemar Máximo, João Magalhães, Giuliana Salvatore, Massimo Santoro, Tatyana Bogdanova, Mykola Tronko, Alexander Abrosimov, Steve Jeremiah, Gerry Thomas, Dillwyn Williams, Manuel Sobrinho-Simões
Publication date
2004/9/1
Journal
The Journal of Clinical Endocrinology & Metabolism
Volume
89
Issue
9
Pages
4267-4271
Publisher
Oxford University Press
Description
The BRAF gene has been shown to be a major target for mutations in papillary thyroid carcinoma (PTC) (36–69%), which forms almost all of the over 2000 cases of thyroid carcinoma that have occurred in Chernobyl. BRAF is activated by point mutation, and were it to occur at a high frequency in Chernobyl-related tumors, it would challenge the dominant role of double-strand breaks in radiation-induced PTC. In a previous study, we detected the BRAF V600E mutation in 46% (23 of 50) of sporadic adult PTC. Using the same methodology, we have analyzed 34 post-Chernobyl PTC and detected RET/PTC rearrangements in 14 (41%) and BRAF mutations (V600E) in four (12%). These two alterations did not coexist in any PTCs. The mean age at exposure of patients with PTC showing BRAF mutation was higher than that of patients with tumors without BRAF mutation irrespective of their RET status. We have also …
Total citations
20042005200620072008200920102011201220132014201520162017201820192020202120222023202412627301812151214121714865774143
Scholar articles
J Lima, V Trovisco, P Soares, V Máximo, J Magalhães… - The Journal of Clinical Endocrinology & Metabolism, 2004